1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686–1696. PMID:
10553730.
2. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities : A five-year naturalistic study. Am J Psychiatry 2000;157:975–981. PMID:
10831479.
3. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006;186:572–578. PMID:
16601995.
4. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290–296. PMID:
12562575.
5. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856–865. PMID:
12416594.
6. Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D. Clozapine and hypertension : a chart review of 82 patients. J Clin Psychiatry 2004;65:686–689. PMID:
15163256.
7. Reaven GM. Role of insulin resistance in human disease. Nutrition 1997;13:65PMID:
9058458.
8. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992;41:715–722. PMID:
1587398.
9. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–689. PMID:
11315831.
10. Correll CU. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr 2007;12(10 Suppl 17):12–20. 35PMID:
17934385.
11. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709–2716. PMID:
12460094.
12. Hong Y, Pedersen NL, Brismar K, de Faire U. Genetic and environmental architecture of the features of the insulin-resistance syndrome. Am J Hum Genet 1997;60:143–152. PMID:
8981957.
13. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000;43:373–376. PMID:
10768099.
14. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002;359:2086–2087. PMID:
12086765.
15. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003;160:677–679. PMID:
12668355.
16. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F, et al. Weight gain associated with the-759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005;134B:76–78. PMID:
15666332.
17. Miller DD, Ellingrod VL, Holman TL, Buckley PF, Arndt S. Clozapine-induced weight gain associated with the 5HT2C receptor-759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005;133B:97–100. PMID:
15635667.
18. Mulder H, Franke B, van der-Beek van der AA, Arends J, Wilmink FW, Scheffer H, et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2007;27:338–343. PMID:
17632216.
19. Luquet S, Lopez-Soriano J, Holst D, Gaudel C, Jehl-Pietri C, Fredenrich A, et al. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie 2004;86:833–837. PMID:
15589693.
20. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, et al. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 1998;7:435–440. PMID:
9467001.
21. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS, et al. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999;84:3708–3712. PMID:
10523018.
22. Poulsen P, Andersen G, Fenger M, Hansen T, Echwald SM, Vølund A, et al. Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thriffy genotype, thriffy phenotype, or both? Diabetes 2003;52:194–198. PMID:
12502512.
23. Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor gamma C161-->T polymorphism and coronary artery disease. Cardiovasc Res 1999;44:588–594. PMID:
10690291.
24. Naito H, Kamijima M, Yamanoshita O, Nakahara A, Katoh T, Tanaka N, et al. Differential effects of aging, drinking and exercise on serum cholesterol levels dependent on the PPARA-V227A polymorphism. J Occup Health 2007;49:353–362. PMID:
17951966.
25. Chan E, Tan CS, Deurenberg-Yap M, Chia KS, Chew SK, Tai ES. The V227A polymorphism at the PPARA locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women. Atherosclerosis 2006;187:309–315. PMID:
16288935.
26. Arulmozhi DK, Dwyer DS, Bodhankar SL. Antipsychotic induced metabolic abnormalities : an interaction study with various PPAR modulators in mice. Life Sci 2006;79:1865–1872. PMID:
16828808.
27. American Psychiatric Association. Diagonstic and Statistical Manual of Mental Disorders. 1994,Fourth Edition. Washington, DC: American Psychiatric Press.
28. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome : an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–2752. PMID:
16157765.
29. World Health Organization. The Asia-Pacific Perspective: Redefing Obesity And Its Treatment. 2000,Sydney: Health Communication Australia; p. 15–21.
30. Jung HY, Park JS, Park YJ, Kim YJ, Kimm K, Koh IS. HapAnalyzer : minimum haplotype analysis system for association studies. Genomics Inform 2004;2:107–109.
31. Mulder H, Cohen D, Scheffer H, Gispen-de Wied C, Arends J, Wilmink FW. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol 2009;29:16–20. PMID:
19142101.
32. Risselada AJ, Vehof J, Bruggeman R, Wilffert B, Cohen D, Al Hadithy AF, et al. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics J 2010;in pressing.
33. Gunes A, Melkersson KI, Scordo MG, Dahl ML. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 2009;29:65–68. PMID:
19142110.
34. Naito H, Yamanoshita O, Kamijima M, Katoh T, Matsunaga T, Lee CH, et al. Association of V227A PPARalpha polymorphism with altered serum biochemistry and alcohol drinking in Japanese men. Pharmacogenet Genomics 2006;16:569–577. PMID:
16847426.
35. Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, et al. Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome. Arch Med Res 2006;37:86–94. PMID:
16314192.
36. Herken H, Erdal M, Aydin N, Sengul C, Karadag F, Barlas O, et al. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol 2009;28:515–519. PMID:
19622037.
37. Nam YY, Kim CS, Ahn CW, Park KM, Ryu B, Kim CH. Clinical correlates of metabolic syndrome in patients with chronic schizophrenia. Korean J Psychopharmacol 2006;17:335–341.
38. Jeong JT, Yoon BH, Kim TU, Sea YH, Park SH, Jeong KY, et al. Prevalence of metabolic syndrome in chronic schizophrenic inpatients. Korean J Schizophr Res 2009;12:83–89.
39. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008;101:295–303. PMID:
18299188.
40. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006;163:1273–1276. PMID:
16816234.